Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients

Antiviral Research

Volumn 113, Issue , 2015, Pages 103-106

  Casado, José L ^a   Bañón, Sara ^a   Rodriguez, Miguel A ^a   Moreno, Ana ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Dual antiretroviral therapy; PI NRTI sparing regimen; Simplification; Toxicity

Indexed keywords

CHOLESTEROL; ETRAVIRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; TRIACYLGLYCEROL; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; MAINTENANCE THERAPY; MINIMUM PLASMA CONCENTRATION; PROSPECTIVE STUDY; RASH; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; ADVERSE EFFECTS; AGED; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MIDDLE AGED; PHYSIOLOGY; VIROLOGY; VIRUS LOAD;

HEPATITIS C VIRUS;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDAZINES; PYRROLIDINONES; VIRAL LOAD;

EID: 84919391756     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.11.006     Document Type: Article

References (17)

1. P. Barreiro, T. Garcia-Benayas, A. Rendon, S. Rodriguez-Novoa, and V. Soriano Combinations of nucleoside/nucleotide analogues for HIV therapy AIDS Rev. 6 2004 234 243
2. R. Calin, L. Paris, A. Simon, G. Peytavin, M. Wirden, L. Schneider, M.A. Valantin, R. Tubiana, R. Agher, and C. Katlama Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy Antiviral Ther. 17 2012 1601 1604
3. J.L. Casado Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine AIDS Rev. 15 2013 139 145
4. J.L. Casado, I. de Los Santos, M. Del Palacio, L. Garcia-Fraile, M.J. Perez-Elias, J. Sanz, and S. Moreno Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART HIV Clin. Trials 14 2013 1 9
5. P. Domingo, M. Gutierrez Mdel, J.M. Gallego-Escuredo, F. Torres, M.G. Mateo, J. Villarroya, K. Lamarca, J.C. Domingo, F. Vidal, F. Villarroya, and M. Giralt A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz J. Acquir. Immune Defic. Syndr. 66 2014 457 465
6. J.J. Eron, D.A. Cooper, R.T. Steigbigel, B. Clotet, J.M. Gatell, P.N. Kumar, J.K. Rockstroh, M. Schechter, M. Markowitz, P. Yeni, M.R. Loutfy, A. Lazzarin, J.L. Lennox, K.M. Strohmaier, H. Wan, R.J. Barnard, B.Y. Nguyen, H. Teppler, and B.S. Teams Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials Lancet Infect. Dis 13 2013 587 596
7. H.F. Gunthard, J.A. Aberg, J.J. Eron, J.F. Hoy, A. Telenti, C.A. Benson, D.M. Burger, P. Cahn, J.E. Gallant, M.J. Glesby, P. Reiss, M.S. Saag, D.L. Thomas, D.M. Jacobsen, and P.A. Volberding Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel JAMA J. Am. Med. Assoc. 312 2014 410 425
8. I. Jarrin, B. Hernandez-Novoa, B. Alejos, I. Santos, J. Lopez-Aldeguer, M. Riera, F. Gutierrez, R. Rubio, A. Antela, J.R. Blanco, S. Moreno Cohort of the Spanish HIV Research Network (CoRIS) Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen HIV Med. 2014
9. T.N. Kakuda, M. Scholler-Gyure, and R.M. Hoetelmans Pharmacokinetic interactions between etravirine and non-antiretroviral drugs Clin. Pharmacokinet. 50 2011 25 39
10. C. Katlama, L. Assoumou, M.A. Valantin, C. Soulie, C. Duvivier, L. Chablais, S. Kolta, G. Pialoux, P. Mercie, A. Simon, D. Costagliola, G. Peytavin, A.G. Marcelin ROCnRAL ANRS 157 Study Group Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study J. Antimicrob. Chemother. 69 2014 1648 1652
11. E. Martinez, M. Larrousse, J.M. Llibre, F. Gutierrez, M. Saumoy, A. Antela, H. Knobel, J. Murillas, J. Berenguer, J. Pich, I. Perez, J.M. Gatell SPIRAL Study Group Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study AIDS 24 2010 1697 1707
12. A. Menard, C. Solas, S. Mokthari, S. Bregigeon, M.P. Drogoul, C. Tamalet, B. Lacarelle, and I.P. Martin Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases AIDS 23 2009 869 871
13. P. Monteiro, I. Perez, M. Laguno, M. Martinez-Rebollar, A. Gonzalez-Cordon, M. Lonca, J. Mallolas, J.L. Blanco, J.M. Gatell, and E. Martinez Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study J. Antimicrob. Chemother. 69 2014 742 748
14. J.M. Poirier, P. Robidou, and P. Jaillon Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 867 2008 277 281
15. M.L. Ramirez, F.X. Vargas, J. Gonzalez-Garcia, C. Quereda, M.J. Perez-Elias, A.M. de Cea, C. Barros, E. Condes, J.S. Moreno, I. Santos, M. Torralba, T. Aldamiz-Echevarria, and A. Moreno Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir AIDS 28 2014 2487 2489
16. M.L. Rizk, Y. Hang, W.L. Luo, J. Su, J. Zhao, H. Campbell, B.Y. Nguyen, P. Sklar, J.J. Eron Jr., and L. Wenning Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients Antimicrob. Agents Chemother. 56 2012 3101 3106
17. L. Ryom, A. Mocroft, O. Kirk, S.W. Worm, D.A. Kamara, P. Reiss, M. Ross, C.A. Fux, P. Morlat, O. Moranne, C. Smith, J.D. Lundgren D:A:D Study Group Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D: A: D study J. Infect. Dis. 207 2013 1359 1369